Navigation Links
Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Date:9/18/2007

of their treated tumors, 25% achieved an objective response of their untreated bystander tumors, and 100% exhibited disease control in their bystander tumors. In contrast, for those subjects failing to achieve an objective response of their treated tumors, only 8% achieved an objective response of their bystander tumors, and 92% exhibited progressive disease in their bystander tumors. These differences in response of bystander lesions as a function of response of target lesions were statistically significant and support the occurrence of a bystander effect in subjects whose target lesions have been responsive to PV-10 chemoablation.

Craig Dees, Ph.D., Chief Executive Officer of Provectus stated, "While full analysis of our phase 1 data is yet to be completed and will be reported by other means, the significance of these top line numbers is compelling and serves to illustrate the unique properties of Provecta. Additionally, they reinforce the confidence level we've had since we first witnessed the effects of this drug for the treatment of melanoma. These results have motivated us to put forth an aggressive clinical plan designed to drive toward approval of Provecta for this devastating disease." Dees continued, "The response from the body's own immune system to those tumors that were left untreated makes our novel approach to treating the disease that much more attractive."


'/>"/>

Contact: Janet Vasquez
212-825-3210
Provectus Pharmaceuticals
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Sweet corn releases antioxidants on cooking
2. An International Growth Standard For Childs Releases By WHO
3. The National Governors Association Releases Guidelines For Outbreak Of Bird Flu
4. Eli Lilly Releases Digital Insulin Pen
5. Experimental treatment for Ebola Virus Shows promising results in mice
6. Hormone Deficiency Results In Miscarriage
7. Gleevec gets hopeful results
8. Breast Implants May Interfere With The Interpretation Of Mammogram Results
9. DNA Testing For More Accurate Results
10. Operating on a Beating Heart Yields Better Results For Blocked Heart Arteries
11. IVF results may be affected by stress and other related factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter , ... on Monday officially tightened guidelines for health workers treating Ebola ... and use of a respirator at all times. The ... the tougher rules after two Dallas nurses contracted Ebola while ... States, Liberian national Thomas Eric Duncan. Nina Pham is currently ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... Pittsburgh, PA (PRWEB) October 20, 2014 ... new, minimally-invasive procedure that enables physicians to repair a ... , The MitraClip system, developed by ... regurgitation (MR), a progressive and life-threatening condition in which ... allowing blood to flow backward from the heart’s left ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... BEER-SHEVA, ISRAEL, December 17, 2010 As middle ear ... University of the Negev (BGU) suggest that in many ... instead of using antibiotics immediately. The review, published ... Therapy , does not suggest use of watchful waiting ...
... -- Differences in immune signaling pathways among various species ... primates to certain infectious diseases, researchers say. For ... to AIDS or severe complications from hepatitis B, it ... chimpanzees to the serious effects of these viral infections, ...
... News) Christmas and other winter holidays are supposed to ... the more stressful when they are anything but joyous. ... especially vulnerable to depression, Dr. Angelos Halaris, a psychiatrist with ... release. Shopping and entertaining can be stressful, while reflecting on ...
... research indicates that about half of women age 65 and ... place, the poverty rate for women falls to 12 percent. ... are presented in the latest installment of the Public ... on an Aging Society, the public policy branch of The ...
... THURSDAY, Dec. 16 (HealthDay News) -- U.S. scientists have unraveled ... cancer in children. Gene sequencing reveals that this tumor, ... adult tumors. The discovery that MB has five to ... attempts to understand what triggers the cancer and which treatment ...
... , , , , , ... , AUDIO: People with a known risk ... Click here for more information. , , ... , , , , , ...
Cached Medicine News:Health News:Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children 2Health News:Primate Immune System Differences Identified 2Health News:Surviving the Holiday Blues 2Health News:Brief clarifies Social Security's value for women 2Health News:Gene Research Brings Insight Into Deadly Childhood Brain Tumor 2Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 2Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 3Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 4Health News:MRI scans reveal brain changes in people at genetic risk for Alzheimer's 5
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/22/2014)... JOLLA, Calif. , Oct. 22, 2014 ... RGLS ), a biopharmaceutical company leading the ... microRNAs, today announced that it has demonstrated ... an ongoing clinical study evaluating RG-101, a ... the treatment of hepatitis C virus infection ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014  PneumRx, Inc. ... interventional pulmonology, today announced completion of enrollment in their ... RENEW Clinical Study is the FDA-approved IDE pivotal trial ... severe emphysema. It was anticipated that the ... February 2013, would take until the end of 2014 ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium ... today positive preliminary results from its Phase II ... prednisone (D/P) in men with docetaxel refractory, castrate ... of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in ...
... Feb. 26 /PRNewswire-FirstCall/ -- MannKind Corporation ... the status of its new drug application ("NDA") for AFRESA(R), ... trials. As previously announced, our internal goal was to ... by the end of February. Based on editorial decisions ...
Cached Medicine Technology:Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 2Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 3Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 4MannKind Updates Status of NDA Submission for AFRESA 2MannKind Updates Status of NDA Submission for AFRESA 3
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: